- Conditions
- Metastatic Melanoma
- Interventions
- Cyclophosphamide and Interleukin 2
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 265–288
of 671
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Bevacizumab, Interleukin-2
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Melanoma, Metastatic Kidney Cancer
- Interventions
- Natural Killer (NK) Lymphocytes, IL-2, Cyclophosphamide, Fludarabine
- Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Melanoma, Kidney Cancer
- Interventions
- Not listed
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Beaumont, California
- Conditions
- Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Ovarian Carcinosarcoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
- Interventions
- Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine, Interleukin-2, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
- Interventions
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Drug
- Lead sponsor
- Medicenna Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 7
- States / cities
- San Diego, California • San Francisco, California • Santa Monica, California + 4 more
- Conditions
- Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
- Interventions
- KITE-439, Cyclophosphamide, Fludarabine, Interleukin-2
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Gilbert, Arizona • Duarte, California • Los Angeles, California + 6 more
- Conditions
- Liver Cirrhosis, Hepatocellular Carcinoma, Evidence of Liver Transplantation
- Interventions
- Liver NK cell inoculation
- Biological
- Lead sponsor
- Seigo Nishida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma, Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis), Leukemia
- Interventions
- GM-CSF, IL-2
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2011
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Acute Myelogenous Leukemia, Refractory Acute Myelogenous Leukemia
- Interventions
- Allopurinol, Fludarabine, Total body irradiation, Cyclophosphamide, Levetiracetam, Busulfan, Umbilical Cord Blood Transplantation, Interleukin-2
- Drug · Radiation · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 2 Years to 45 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- IOV-2001, Low dose IL-2, High dose IL-2, IL-2
- Biological · Drug
- Lead sponsor
- Iovance Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 7
- States / cities
- Tampa, Florida • Durham, North Carolina • Cincinnati, Ohio + 4 more
- Conditions
- Kidney Cancer
- Interventions
- 117-126:Fibroblast growth factor 5 (FGF-5), Fibroblast growth factor 5 (FGF-5):172-176/217-220, IL-2
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 16 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Breast Cancer
- Interventions
- Fludarabine, Cyclophosphamide, Cyclosporine, Natural killer cells, IL-2, Methylprednisolone, Interleukin-2
- Drug · Biological
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, recombinant interferon alfa, sargramostim, temozolomide
- Biological · Drug
- Lead sponsor
- Saint Francis Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2003
- U.S. locations
- 3
- States / cities
- San Francisco, California • Santa Monica, California • Aurora, Colorado
- Conditions
- Solid Tumor, Cancer, Recurrent Solid Tumors, Refractory Solid Tumors
- Interventions
- IMA201 Product, IMADetect®
- Biological · Diagnostic Test
- Lead sponsor
- Immatics US, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- Prostatic Neoplasms
- Interventions
- MVA-MUC1-IL2
- Biological
- Lead sponsor
- Transgene
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Los Angeles, California • Cleveland, Ohio
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infection
- Interventions
- Genetically Marked Syngeneic T Lymphocytes
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1993 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kidney Cancer
- Interventions
- aldesleukin, bevacizumab
- Biological
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Maywood, Illinois • Indianapolis, Indiana + 8 more
- Conditions
- Kidney Cancer
- Interventions
- aldesleukin, sargramostim, vinblastine sulfate
- Biological · Drug
- Lead sponsor
- Hope Cancer Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 2
- States / cities
- Kansas City, Kansas
- Conditions
- Neuroblastoma
- Interventions
- Fludarabine, Cyclophosphamide, Natural Killer Cell Infusion, Mesna, Interleukin-2
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infection
- Interventions
- Recombinant Interleukin-2
- Drug
- Lead sponsor
- Case Western Reserve University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- HIV Infection
- Interventions
- Zidovudine (AZT) & Interleukin-2 (IL2)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Kita-kyushu Lung Cancer Antigen 1, Human
- Interventions
- IL-2 (Aldesleukin), Cyclophosphamide, KK-LC-1 TCR, Fludarabine, EKG, CXR, CT, MRI, PET, Biopsy, Acetaminophen, Ondansetron, Meperidine, Indomethacin, Famotidine
- Drug · Biological · Diagnostic Test + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Acquired Immunodeficiency Syndrome, HIV Infection
- Interventions
- IL-2 plus Anti-TNF or Thalidomide
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2002
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland